Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
The emergence of new therapies for the treatment of rheumatoid arthritis (RA), the paucity of head-to-head studies, and the heterogeneous nature of responses to current biologics highlight the need for the identification of prognostic factors for treatment response and retention in clinical practice...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 July 2015
|
| In: |
BMC musculoskeletal disorders
Year: 2015, Jahrgang: 16 |
| ISSN: | 1471-2474 |
| DOI: | 10.1186/s12891-015-0636-9 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12891-015-0636-9
|
| Verfasserangaben: | Hubert G. Nüßlein, Rieke Alten, Mauro Galeazzi, Hanns-Martin Lorenz, Michael T. Nurmohamed, William G. Bensen, Gerd R. Burmester, Hans-Hartmut Peter, Karel Pavelka, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars |
| Zusammenfassung: | The emergence of new therapies for the treatment of rheumatoid arthritis (RA), the paucity of head-to-head studies, and the heterogeneous nature of responses to current biologics highlight the need for the identification of prognostic factors for treatment response and retention in clinical practice. Prognostic factors for patient retention have not been explored thoroughly despite data for abatacept and other biologics being available from national registries. Real-world data from the ACTION study may supplement the findings of randomized controlled trials and show how abatacept is used in clinical practice. The aim of this interim analysis was to identify prognostic factors for abatacept retention in patients with RA who received at least one prior biologic agent. |
|---|---|
| Beschreibung: | Gesehen am 22.02.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-2474 |
| DOI: | 10.1186/s12891-015-0636-9 |